Characterization of pain in fabry disease

Clinical Journal of Pain

Volumn 30, Issue 10, 2014, Pages 915-920

  Üçeyler, Nurca ^a   Ganendiran, Shalni ^a   Kramer, Daniela ^a   Sommer, Claudia ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Evoked pain; Fabry disease; Neuropathic pain; Pain attacks; Pain crisis; Pain trigger

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; CARBAMAZEPINE; DIPYRONE; GABAPENTIN; IBUPROFEN; NAPROXEN; PARACETAMOL; PHENYTOIN; PREGABALIN; TILIDINE; TRAMADOL; VENLAFAXINE; ANALGESIC AGENT;

ADULT; AGED; ARTICLE; BURNING SENSATION; CHRONIC PAIN; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DYSESTHESIA; FABRY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PAIN; PAIN INTENSITY; PAIN SEVERITY; PARESTHESIA; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STIMULATION; ADOLESCENT; ANALGESIA; COMPLICATION; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRE; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS; COHORT STUDIES; DEPRESSION; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; QUESTIONNAIRES; SEX FACTORS; YOUNG ADULT;

EID: 84923543469     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0000000000000041     Document Type: Article

References (23)

1. Toyooka K. Fabry disease. Curr Opin Neurol. 2011;24: 463-468
2. Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61
3. Kaye EM, Kolodny EH, Logigian EL, et al. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol. 1988;23:505-509
4. Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet. 1983;20:309-312
5. Liguori R, Di Stasi V, Bugiardini E, et al. Small fiber neuropathy in female patients with fabry disease. Muscle Nerve. 2010;41:409-412
6. Laaksonen SM, Roytta M, Jaaskelainen SK, et al. Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol. 2008;119:1365-1372
7. Torvin Moller A, Winther Bach F, Feldt-Rasmussen U, et al. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain. 2009;145:237-245
8. Biegstraaten M, Binder A, Maag R, et al. The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain. 2011;15:822-829
9. Üçeyler N, He L, Schönfeld D, et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst. 2011;16:304-314
10. Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-A retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23:535-542
11. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-760
12. Sommer C, Richter H, Rogausch JP, et al. A modified score to identify and discriminate neuropathic pain: a study on the German version of the neuropathic pain symptom inventory (NPSI). BMC Neurol. 2011;11:104
13. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257
14. Von Korff M, Ormel J, Keefe FJ, et al. Grading the severity of chronic pain. Pain. 1992;50:133-149
15. Radloff LS. The CES-D: a self-report symptom scale to detect depression in the general population. Appl Psychol Meas. 1977;3:385-401
16. Gibas AL, Klatt R, Johnson J, et al. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag. 2006;11:185-192
17. Hughes DA, Barba Romero MA, Hollak CE, et al. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-The Fabry Outcome Survey. Mol Genet Metab. 2011;103:207-214
18. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16
19. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749
20. Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics. 2005;115:e344-e355
21. Castaneda JA, Lim MJ, Cooper JD, et al. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 2008;115:159-174
22. De Francesco PN, Mucci JM, Ceci R, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109: 93-99
23. Arning K, Naleschinski D, Maag R, et al. FabryScan: a screening tool for early detection of Fabry disease. J Neurol. 2012;259:2393-2400.